IBCL-549: Two-Year Rituximab Maintenance vs Observation After First-Line Treatment With Bendamustine Plus Rituximab in Patients With Waldenström’s Macroglobulinemia: Results of a Prospective, Randomized Multicenter Phase 3 Study (StiL NHL7-2008 MAINTAIN Trial)
Mathias Rummel, Tobias Arnold, Christian Lerchenmüller, Manfred Hensel et autres